NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Lumos Pharma
Incyte Corporation
NanOlogy, LLC
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
Gilead Sciences
National Cancer Institute (NCI)